Gilead Sciences, Inc. (GILD) stock analysis
Company overview and business model
Source fact: Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Classification: NASDAQ · Healthcare · Drug Manufacturers - General
Revenue and growth
Source fact: Revenue was USD 29.44 billion for the period ending 2025-12-31.
Caverian calculation: Revenue changed +2.4% (FY2025 vs FY2024).
Profitability
Source fact: Net income was USD 8.51 billion in the latest reported period.
Source metric: Reported net margin was 28.9%.
Balance sheet and liquidity
Source fact: Cash and equivalents were USD 7.56 billion.
Source fact: Total debt was USD 24.94 billion.
Source metric: Current ratio was 1.55x.
Cash-flow analysis
Source fact: Operating cash flow was USD 10.02 billion.
Source fact: Free cash flow was USD 9.46 billion.
Valuation
Source metrics: Forward P/E 14.77x; Price to book 15.33x; Price to sales 5.95x; EV/EBITDA 13.87x.
Caverian model output: Value score was 30/100.
Competitive position
Classification: Peer context: Drug Manufacturers - General within Healthcare.
Caverian model output: Quality score was 79/100.
Caverian model output: Growth score was 64/100.
Material risks
Caverian calculation: Altman Z-score was 4.55 (safe zone).
Caverian calculation: Piotroski F-score was 8/9.
Data sources and freshness
Freshness: This report uses a stored upstream snapshot; statement periods are shown alongside the figures.
Methodology and limitations
Facts reproduce stored upstream fields. Calculations derive only from the displayed stored statements. Model outputs are Caverian interpretations, not investment advice or a buy/sell recommendation.
How Caverian approaches valuation · Sources and product principles